TrialProstate cancer and prostatic diseases2025

Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab.

Andrew B Nixon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.